Loading clinical trials...
Loading clinical trials...
This study is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of LibiGel 300mcg in the treatment of HSDD in surgically menopausal women.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
BioSante Pharmaceuticals
NCT02714049 · Hypoactive Sexual Desire Disorder
NCT03619005 · Hypoactive Sexual Desire Disorder (HSDD)
NCT04336891 · Hypoactive Sexual Desire Disorder, Vulvovaginal Disease, and more
NCT02593396 · Sexual Dysfunctions, Psychological, Hypoactive Sexual Desire Disorder, and more
NCT02968342 · Menopause, Sexual Desire Disorder, and more
BioSante Site #146
Mobile, Alabama
BioSante Site #171
Chandler, Arizona
BioSante Site #145
Glendale, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions